# US 2023/0057197 A1 · Solid state forms of mavacamten and process for preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057197 A1
- Document ID: US20230057197A1
- Status: Published application
- Kind: A1
- Application number: 17/792,754
- Filed: 2021-01-28
- Published: 2023-02-23
- Earliest claimed: 2020-01-28
- Assignees: Teva Pharmaceuticals International GmbH
- Applicants: Teva Pharmaceuticals International GmbH
- Inventors: Lorena Kordic; Dijana Skalec Samec
- Web page: https://patentgrep.com/patent/US20230057197A1

## CPC

- C07D 239/10: Oxygen or sulfur atoms
- C07D 239/545: with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure encompasses solid state forms of Mavacamten, in embodiments crystalline polymorphs of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.

## Claims

### Claim 1

A crystalline form of Mavacamten designated as Form 1, characterized by an X-ray powder diffraction pattern having peaks at 11.7, 16.3, 18.7, 20.0 and 23.4 degrees 2-theta±0.2 degrees 2-theta.

### Claim 2 (depends on 1)

The crystalline Form 1 of Mavacamten according to claim 1, characterized by an XRPD having peaks at: 11.7, 16.3, 18.7, 20.0 and 23.4 degrees 2-theta±0.2 degrees 2-theta; and further characterized by having one, two or three additional peaks selected from 17.4, 29.1 and 31.6 degrees 2-theta±0.2 degrees 2-theta.

### Claim 3 (depends on 2)

The crystalline Form 1 of Mavacamten according to claim 2, wherein said crystalline Form 1 is characterized by an XRPD having peaks at: 11.7, 16.3, 17.4, 18.7, 20.0, 23.4, 29.1 and 31.6 degrees 2-theta±0.2 degrees 2-theta.

### Claim 4 (depends on 1)

The crystalline form of Mavacamten according to claim 1, characterized by the X-ray powder diffraction pattern substantially as depicted in FIG. 1.

### Claim 5 (depends on 1)

The crystalline Form 1 of Mavacamten according to claim 1, wherein said form is an anhydrous form.

### Claim 6

A crystalline form of Mavacamten designated as Form 5, characterized by an X-ray powder diffraction pattern having peaks at 13.4, 14.8, 21.8, 23.8 and 24.6 degrees 2-theta±0.2 degrees 2-theta.

### Claim 7 (depends on 6)

The crystalline Form 5 of Mavacamten according to claim 6, wherein said crystalline is characterized by an XRPD having peaks at: 13.4, 14.8, 21.8, 23.8 and 24.6 degrees 2-theta±0.2 degrees 2-theta; and further characterized by having one, two, three or four additional peaks selected from 11.9, 15.8, 18.9 and 20.1 degrees 2-theta±0.2 degrees 2-theta.

### Claim 8 (depends on 7)

The crystalline Form 5 of Mavacamten according to claim 7, wherein said crystalline Form 5 is characterized by an XRPD having peaks at: 11.9, 13.4, 14.8, 15.8, 18.9, 20.1, 21.8, 23.8 and 24.6 degrees 2-theta±0.2 degrees 2-theta.

### Claim 9 (depends on 6)

The crystalline Form 5 of Mavacamten according to claim 6, characterized by the X-ray powder diffraction pattern substantially as depicted in FIG. 5.

### Claim 10 (depends on 6)

The crystalline Form 5 of Mavacamten according to claim 6, wherein said form is an anhydrous form.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the crystalline Form 1 of Mavacamten according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 12

(canceled)

### Claim 13 (depends on 1, 11)

A process for preparing the pharmaceutical composition according to claim 11, comprising combining the crystalline Form 1 of Mavacamten according to claim 1 with at least one pharmaceutically acceptable excipient.

### Claim 14 (depends on 1)

A medicament comprising the crystalline Form 1 of Mavacamten according to claim 1.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of treating obstructive hypertrophic cardiomyopathy (oHCM), comprising administering a therapeutically effective amount of the crystalline Form 1 of Mavacamten according to claim 1 to a subject in need of the treatment.

### Claim 17 (depends on 7)

A pharmaceutical composition comprising the crystalline Form 5 of Mavacamten according to claim 7 and at least one pharmaceutically acceptable excipient.

### Claim 18 (depends on 7)

A process for preparing a pharmaceutical composition comprising combining the crystalline Form 5 of Mavacamten according to claim 7 with at least one pharmaceutically acceptable excipient.

### Claim 19 (depends on 7)

A medicament comprising the crystalline Form 5 of Mavacamten according to claim 7.

### Claim 20 (depends on 7)

A method of treating obstructive hypertrophic cardiomyopathy (oHCM), comprising administering a therapeutically effective amount of the crystalline Form 5 of Mavacamten according to claim 7 to a subject in need of the treatment.
